Invokana, Invokamet, and Invokamet XR have been linked to an increased risk of amputation.
New Yorker Giacomo Lo Re died after taking a diabetes drug that federal regulators later warned may cause infections like the one that killed him.
Now, Lo Re’s widow, Venera, is suing the drug’s maker, Johnson & Johnson, claiming the pharmaceutical giant and affiliates misled the public about its risks in pursuit of related drug sales that totaled $1.1 billion in 2017, according to court and financial records. The lawsuit also accused health care providers, including Rochester Regional Health, of failing to properly treat the Wayne County man in connection to his wrongful death at 68.
READ MORE: DemocratandChronicle.com
Certain medications used to treat diabetes have been linked to cases of a rare, potentially deadly flesh-eating genital infection, the Food and Drug Administration announced this week.
The medications affected: sodium-glucose cotransporter-2 (SGLT2) inhibitors, which are used in the treatment of type 2 diabetes. A Wednesday release from the FDA lists more than a dozen drugs that will have to warn of the infection. Among the brand names listed: Invokana, Farxiga and Jardiance.
READ MORE: USAToday.com
Johnson & Johnson has agreed to settle a large chunk of lawsuits over its diabetes drug Invokana.
In an Oct. 16 motion, Michael London, of New York-based Douglas & London, who is co-lead plaintiffs’ counsel in the multidistrict litigation in New Jersey, asked the court to set up a qualified settlement fund of a “confidential settlement amount” to resolve his inventory of cases.
READ MORE: New Jersey Law Journal
Based on new data from two large clinical trials, the U.S. Food and Drug Administration (FDA) has concluded that the type 2 diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR) causes an increased risk of leg and foot amputations. We are requiring new warnings, including our most prominent Boxed Warning, to be added to the canagliflozin drug labels to describe this risk.
READ MORE: FDA Notice
Invokana, a diabetes drug made by Johnson & Johnson, decreases the risk of heart attacks and strokes, but also increases the risk of amputation, particularly of toes.
READ MORE: Forbes
Johnson & Johnson (JNJ.N) is required to add new warnings to its diabetes drug, Invokana, about the risk of foot and leg amputations, the U.S. Food and Drug Administration said on Tuesday.
Final results from two clinical trials showed leg and foot amputations occurred about twice as often in patients with type 2 diabetes treated with Invokana, known also as canagliflozin, as those given a placebo, the FDA said in an announcement posted on its website.
READ MORE: Reuters
• Heart attack, stroke, death 14 percent lower with Invokana
• Higher rate of amputations and fractures could limit use
Johnson & Johnson’s pill Invokana reduced the risk of cardiovascular complications in diabetic patients, making it the second medication of its kind to help the heart, but the benefit came with an increased risk of amputations and perhaps broken bones, researchers said.
READ MORE: Bloomberg